US 12,168,060 B2
Antibody-drug conjugates comprising anti-B7-H3 antibodies
Taekyo Park, Daejeon (KR); Sunyoung Kim, Daejeon (KR); Suho Park, Daejeon (KR); Doohwan Jung, Daejeon (KR); Donghoon Seo, Daejeon (KR); Sangkwang Lee, Daejeon (KR); Sanghyeon Yun, Daejeon (KR); Jihyeon Ha, Daejeon (KR); Hyang Sook Lee, Daejeon (KR); Okku Park, Daejeon (KR); Beomseok Seo, Daejeon (KR); Sena Kim, Daejeon (KR); Minah Seol, Daejeon (KR); Jina Song, Daejeon (KR); Sung Ho Woo, Daejeon (KR); Jongun Cho, Daejeon (KR); Jaeho Lee, Sejong-Si (KR); Hyun Mi Lee, Daejeon (KR); Jae Eun Park, Daejeon (KR); Youngja Song, Daejeon (KR); Eunjin Lee, Daejeon (KR); Hyun Ju Lee, Daejeon (KR); Eun-Young Shim, Daejeon (KR); Yunjung Ko, Daejeon (KR); Minju Lee, Daejeon (KR); Young woo Park, Daejeon (KR); and Yosup Rew, Daejeon (KR)
Assigned to IntoCell, Inc., Daejeon (KR); and Y-Biologics Inc., Daejeon (KR)
Filed by IntoCell, Inc., Daejeon (KR); and Y-Biologics Inc., Daejeon (KR)
Filed on Jun. 25, 2021, as Appl. No. 17/358,306.
Claims priority of provisional application 63/044,764, filed on Jun. 26, 2020.
Prior Publication US 2022/0047717 A1, Feb. 17, 2022
Int. Cl. A61K 47/68 (2017.01); C07K 16/28 (2006.01)
CPC A61K 47/6849 (2017.08) [A61K 47/6813 (2017.08); A61K 47/6817 (2017.08); A61K 47/6851 (2017.08); C07K 16/2827 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A antibody conjugate represented by Formula I or pharmaceutically acceptable salt or solvate thereof:
Ab-(G)n  Formula I
wherein:
Ab is an anti-B7-H3 antibody or antigen-binding fragment thereof comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein,
CDRH1 comprises an amino acid sequence of SEQ ID NO: 1,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 2,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 3,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 4,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 5, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 6; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 7,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 8,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 9,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 10,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 11, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 12; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 13,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 14,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 15,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 16,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 17, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 18; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 19,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 20,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 21,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 22,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 23, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 24; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 25,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 26,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 27,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 28,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 29, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 30; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 31,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 32,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 33,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 34,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 35, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 36; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 37,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 38,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 39,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 40,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 41, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 42; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 43,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 44,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 45,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 46,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 47,
CDRL3 comprises an amino acid sequence of SEQ ID NO: 48;
and further wherein:
each G is, independently, a chemical moiety comprising one or more active agents and a linker, wherein the linker links Ab to the active agent(s); and
n is an integer between 1 to 20.